No replies to this topic

[Health Reporter]

Advertisement

Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome.

Colorectal Dis. 2012 Jun 27;

Authors: Banasiewicz T, Krokowicz L, Stojcev Z, Kaczmarek BF, Kaczmarek E, Maik J, Marciniak R, Krokowicz P, Walkowiak J, Drews M

Abstract
Aim:  Abdominal pain, defaecation disorder and change of bowel habit are the commonest symptoms of irritable bowel syndrome (IBS). The effect of microencapsulated sodium butyrate (MSB) was assessed on the severity of symptoms in patients with IBS. Method:  66 patients treated with one of the standard pharmacological therapies for at least 3 months were included in the study. They were randomized to receive MSB as a supplemental treatment to standard therapy or to receiving a placebo. Previous pharmacological therapy was continued throughout the study in both arms. Clinical evaluation was performed at baseline, 4 and 12 weeks. Each assessment was documented by a validated visual analogue score questionnaire (VAS-IBS) measuring severity of selected clinical symptoms, a closed-end questionnaire measuring the frequency of selected clinical symptoms and a single closed-end questionnaire measuring subjective improvement of symptoms. Results:  After 4 weeks there was, a significant decrease of pain during defecation in the MSB group which extended to improvement of, urgency and bowel habit at 12 weeks. Reduction of abdominal pain, flatulence and disordered defecation was not statistically significant. Conclusions:  MSB as a supplemental therapy can reduce the frequency of selected clinical symptoms in patients with IBS, without significant influence on reducing symptom severity. © 2012 The Authors Colorectal Disease © 2012 The Association of Coloproctology of Great Britain and Ireland.

PMID: 22738315 [PubMed - as supplied by publisher]

View the full article